-
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)
Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
Nadecnemab: Advancing Cancer Research Through Anti-CD47 Targeting(Post)Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does
Pamrevlumab: Unveiling the Potential of Anti-Fibrotic Therapy in Clinical Trials and Research(Post)Quick Facts About PamrevlumabWhat is Pamrevlumab?Pamrevlumab (FG-3019) is a monoclonal antibody designed to target and inhibit the connective tissue growth factor (CTGF), a key driver of
Cation and Inorganic Ion Assays(Page) Understanding Platelet Activation: A Comprehensive Overview(Post)Haemostasis · Platelet BiologyUnderstanding Platelet Activation: A Comprehensive OverviewPlatelet activation is the rapid, tightly controlled response by which circulating platelets change shape, rele
The IL-36 Subfamily | Expression, Function & Regulation(Post)By Charlotte O'Donnell PhD The genes of the IL-36 family members are located in a cluster on chromosome 2 [1]. All three activating ligands, IL-36α, IL-36β a
CD4 T-Helper Differentiation: Th1, Th2, Th17, Treg and Tfh(Post)The antigen tells a CD4 T cell to respond; the cytokine tells it what kind of response to make. A naive CD4⁺ T cell leaving the thymus is uncommitted. Within about seventy-two hours of engaging TCR/C
cGAS-STING cytosolic DNA sensing(Page) Adaptive immune system molecules(Page) Icatolimab: Revolutionizing the Fight Against Cancer via CD47 Targeting(Post)Quick Facts About IcatolimabWhat is Icatolimab?Icatolimab is a monoclonal antibody designed to target CD47, a protein that cancer cells use to evade immune detection.How does Icatolimab
IgE and Mast Cells: The Cell Is Armed in Advance(Post)The mast cell is loaded long before the allergen arrives. IgE bound to FcεRIα is not waiting to be recruited the way an antibody waits for antigen in a serum assay — it is already installed on the ce
The Leukocyte Adhesion Cascade: Integrin Signalling and Assays(Post)Every leukocyte that reaches an inflamed tissue has solved the same mechanical problem. It must stop, in under a second, against a shear flow that would otherwise sweep it past the site of infection.
Anti-PD-L1: Targeting Tumor Evasion with Immune Checkpoint Blockade(Post)IntroductionCancer cells have developed sophisticated mechanisms to evade the immune system, particularly through the inhibition of T-cell responses. One such mechanism involves the progr
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
Farletuzumab: Advancing Antibody-Drug Conjugate Research in Ovarian Cancer(Post)Quick Facts About FarletuzumabWhat is Farletuzumab?Farletuzumab is a humanized monoclonal antibody targeting folate receptor alpha (FRα), a protein overexpressed in ovarian and other epi
Tisotumab Vedotin: A Breakthrough in Targeted Cancer Therapy(Post)Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved for
Aducanumab: Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Facts About AducanumabWhat is Aducanumab?Aducanumab is a monoclonal antibody designed to target and reduce amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease.What
Glenzocimab: A Novel Antiplatelet Therapy for Stroke Prevention(Post)Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycopr
After Tocilizumab, IL-6 Goes Up. That Is the Drug Working.(Post)Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b
COVID-19 15分のRAPID POCテスト(Post)COVID-19 15分のRAPID POCテスト 詳細については、hello @ assaygenie.comにお問い合わせください。 概観 Acro Biot